Acrylates
- Name
- Acrylates
- Accession Number
- DBCAT001443
- Description
Derivatives of acrylic acid (the structural formula CH2=CHCO2H), including its salts and esters.
- Drugs
Drug Drug Description trans-urocanic acid Not Available Myxothiazol Not Available AP5280 Investigated for use/treatment in solid tumors. Azoxystrobin Azoxystrobin is a methoxyacrylate analog and a strobilurin fungicide. Osimertinib A tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung carcinoma. Spebrutinib Spebrutinib has been used in trials studying the treatment of Rheumatoid Arthritis, Lymphoma, Large B-Cell, Diffuse, and Leukemia Lymphocytic Chronic B-Cell. Rociletinib Rociletinib has been used in trials studying the treatment and prevention of Nonsmall Cell Lung Cancer, Non-small Cell Lung Cancer, and Locally Advanced or Metastatic Non-small Cell Lung Cancer. Ozagrel Ozagrel has been used in trials studying the treatment of Dry Eye Syndromes. 2-octyl cyanoacrylate Dermabond has been investigated for the basic science of Wound Healing. Verdinexor Kpt 335 is under investigation in clinical trial NCT02431364 (Trial of Safety and Tolerability of Oral Verdinexor (Verdinexor) in Healthy Adults). Enbucrilate Enbucrilate is under investigation in clinical trial NCT02468206 (Secondary Prophylaxis of Gastric Variceal Bleed). PAC-14028 PAC-14028 has been used in trials studying the treatment of Skin Pruritus, Papulopustular Rosacea, and Erythematotelangiectatic Rosacea. Daporinad Daporinad has been used in trials studying the treatment of Melanoma, Cutaneous T-cell Lymphoma, and B-cell Chronic Lymphocytic Leukemia. ACT-451840 ACT-451840 has been used in trials studying Malaria. Pyrotinib Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer). Ocrylate Ocrylate is under investigation in clinical trial NCT01918059 (Cosmetic Outcome Study of Lid Laceration Repair With Suture Versus Tissue Adhesive). Almonertinib Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.[A231859, A231864, A231869] It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). Abivertinib Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK). It has been investigated for use in... BLU-9931 Not Annotated - Drugs & Drug Targets